Skip to main content
TipRanks
Go Ultimate75% OFF

Corey Michael Watton Insider Profile

4 Followers

Corey Michael Watton, Director at Zevra Therapeutics, holds 1.80K shares in Zevra Therapeutics (Ticker: ZVRA).

Corey Michael Watton's Trading History

ZVRA
Zevra Therapeutics
Aug 12, 2026DirectorUninformative Buy61.13K$16.34K
ZVRA
Insider Shares: 1.80K (<0.01%)
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Aug 12, 2026Informative Sell$138.38K12,300$11.25-1.30%
Aug 12, 2026Uninformative Buy$61.13K12,300$4.97―
Mar 31, 2025Informative Buy$2.35K300$7.83+24.40%
Oct 16, 2024Informative Buy$3.96K500$7.91+34.50%
Jun 26, 2023Informative Buy$1.63K275$5.94-6.40%

You May Also Like

Corey Michael Watton insider profile FAQ

What is the percentage of profitable transactions made by Corey Michael Watton?
The percentage of profitable transactions made by Corey Michael Watton is 33%.
What is the average return per transaction made by Corey Michael Watton?
The average return per transaction made by Corey Michael Watton is 4.60%.
What stocks does Corey Michael Watton hold?
Corey Michael Watton holds: ZVRA stocks.
What was Corey Michael Watton’s latest transaction?
Corey Michael Watton’s latest transaction was an Uninformative Buy of $61.13K.
What was Corey Michael Watton's most profitable transaction?
Corey Michael Watton’s most profitable transaction was an Informative Buy of ZVRA stock on October 16, 2024. The return on the trade was 34.50%.
What is Corey Michael Watton's role in Zevra Therapeutics?
Corey Michael Watton's role in Zevra Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.